Pharma Case Interview: Drug Launch, Pipeline Valuation, and Pricing Strategy (2026)

The drug pricing case is one of the hardest problem types in consulting interviews—not because the math is complicated, but because the business model is unlike anything in other industries. A pharma company can spend $2 billion and 12 years developing a drug that fails in Phase III. If it succeeds, it has 10–15 years of patent exclusivity before generics destroy 90% of revenue overnight.

That context shapes every strategic decision. Here's how to navigate pharma cases.

The Pharma Business Model in 90 Seconds

The pharma P&L is radically different from standard businesses:

The average approved drug costs approximately $2.6 billion to bring to market, according to a 2016 Tufts CSDD study. Once approved, it competes in a window of patent-protected exclusivity—typically 10–12 years from market launch before generic competition.

This explains why pharma drugs are expensive: the revenue from successful drugs must recoup the cost of the 9 out of 10 candidates that failed.

The Pharma Case Framework (5 Dimensions)

Drug Launch Strategy Case

The most common pharma case type. The question: "Our client has received FDA approval for a new drug. What should the launch strategy look like?"

Worked Example: Oncology Drug Launch

Case prompt: Your client is a large pharma company that has just received FDA approval for a first-in-class cancer immunotherapy for non-small cell lung cancer (NSCLC). The drug shows a 40% improvement in overall survival versus the current standard of care. The client wants to know: what price should it charge, and how should it launch?

Step 1: Clinical profile and differentiation

• Indication: NSCLC (2nd largest cancer type; ~250,000 new US diagnoses/year)
• Clinical differentiation: 40% OS improvement vs. current standard (pembrolizumab/Keytruda)
• This is significant—Keytruda is a $20B+/year drug; a 40% survival improvement is a major clinical advance

Step 2: Market sizing

• US NSCLC new cases: ~250,000/year
• % appropriate for immunotherapy (advanced/metastatic): ~40% = 100,000 patients
• Market penetration in Year 1 (new drug typically captures 5–15% in first year): ~8,000–15,000 patients

Step 3: Competitive pricing

Value-based pricing logic: our drug delivers meaningfully better survival than Keytruda. Using a QALY-based approach: 40% OS improvement on 12-month median survival = ~5 additional months of life at cancer-adjusted quality. At $150,000/QALY, this supports a price premium of $75,000–$90,000 over Keytruda.

Recommended price: $240,000–$260,000/year, a 35–45% premium to Keytruda, anchored on the demonstrated clinical superiority.

Step 4: Revenue potential

Year 3 peak penetration estimate (15% market share): 15,000 patients × $250,000 = $3.75B peak annual revenue

Step 5: Launch execution priorities

1. Payer access: Negotiate Tier 2 formulary placement with commercial insurers and obtain Medicare Part D coverage. Patient assistance program to reduce co-pays for uninsured/underinsured
2. KOL engagement: Target top 200 oncology thought leaders with Phase III data; fund medical education and conference presentations
3. Sales force: Deploy 300-person specialty oncology sales team focused on academic medical centers and cancer centers
4. Launch market sequence: US launch first (largest and fastest reimbursement); Europe in Year 2 (market access negotiations take 12–18 months per country)

Pipeline Valuation Case

The second most common pharma case type: should a pharma company acquire a biotech company with a promising drug in development?

The core framework: Risk-Adjusted NPV (rNPV)

Pipeline drugs are valued by adjusting their peak sales potential for:

• Probability of approval (success rate at each development stage)
• Time to peak sales (discounted cash flows)
• Development cost remaining

Simplified formula: rNPV = (Peak annual sales × Margin × Patent exclusivity years × Probability of approval) − Remaining development cost − Acquisition premium

Example calculation:

A biotech has a Phase II oncology drug:

• Peak annual sales potential if approved: $2B
• Probability of Phase III success and approval: ~20% (industry average for oncology)
• Patent exclusivity remaining at launch: 10 years
• Remaining development cost: $600M
• Estimated operating margin: 50%

rNPV ≈ (20% × $2B × 50% × 10 years) = $2B Minus remaining development cost ($600M) = $1.4B base value Minus typical acquisition premium (30%) = maximum offer ~$1.8B

Market Access and Reimbursement

The "market access" question comes up in launch cases: how do we get payers to cover this drug?

The formulary tier system (US):

Oncology and rare disease drugs are typically on specialty tier, meaning patients pay 20–30% coinsurance. A $250,000 drug means ~$50,000–$75,000 out-of-pocket annually. That's why patient assistance programs (co-pay cards, foundation grants) are essential launch components.

Key Pharma Terms for Interviews

Connecting to Firm-Specific Prep

Different firms weight pharma cases differently:

• ZS Associates: Heavy pharma/commercial analytics focus; expect quantitative pharma cases
• Simon-Kucher: Deep pricing strategy focus; pharma pricing cases are common
• L.E.K.: Pharma M&A and commercial due diligence; pipeline valuation cases

For the broader healthcare context, see healthcare case interview for coverage of hospitals, payers, and digital health cases.

Test Your Knowledge

Sources and Further Reading (checked March 25, 2026)

• Management Consulted — Pharma Case Interview Example: managementconsulted.com/pharma-case-interview-example
• Tufts CSDD Drug Development Cost Study: csdd.tufts.edu/news/drug-development-cost-study
• McKinsey — GlobaPharm Practice Case: mckinsey.com/careers/interviewing/globapharm
• PrepLounge — McKinsey Pharma Pipeline Case: preplounge.com/en/management-consulting-cases/mckinsey-pharma-pipeline-291
• ZS Associates Practice Case: zs.com/careers/hiring-process/case-interview-practice/practice-case-two